Skip to main content
. 2003 Aug;71(8):4506–4515. doi: 10.1128/IAI.71.8.4506-4515.2003

FIG. 3.

FIG. 3.

Phagocytosis of P. chabaudi adami-IRBCs preincubated with sera from mice vaccinated with VR1020/30K, MCP-3/30K, and CTLA4/30K (and control vector DNA). (A) Percentage of macrophages ingesting IRBCs after preincubation with sera. All six groups contained 10 BALB/c mice each. The values are expressed as percentages of macrophages containing IRBCs out of a total of 200 counted. The number of IRBCs contained within an individual macrophage for each vaccine group is also shown. Data are expressed as means ± standard errors of the means. a, P < 0.05; b, P < 0.01; c, P < 0.001; d, P < 0.0001. (B) Percentage of macrophages ingesting IRBCs after incubation with pooled sera from naive (unvaccinated) mice (n = 6) and pooled sera from mice vaccinated with MCP-3/MSP4/5 DNA (n = 6) as a positive control (29). (C) Incubation of macrophages with a monoclonal antibody specific for Fcγ II and Fcγ III receptors inhibits phagocytosis of IRBCs. Macrophages were treated with a α-Fcγ monoclonal antibody, followed by incubation with IRBCs previously exposed to sera from mice vaccinated with each genomic library (30K + α-FCR mAB), or they were left untreated and incubated with IRBCs exposed to sera from vaccinated mice as a positive control (30K). The data shown are expressed as means ± standard errors of the means of the percentages of macrophages ingesting IRBCs. Five serum samples from mice vaccinated with each of the VR1020/30K, MCP-3/30K, and CTLA4/30K libraries were tested, giving a total of 15 individual samples. Treated (30K + α-FCR mAB) and untreated (30K) groups were compared by using the Student t test.